| Entry |
|
|---|
| Name |
Nintedanib esylate (USAN);
Nintedanib ethanesulfonate (JAN);
Ofev (TN)
|
|---|
| Product |
|
|---|
| Formula |
C31H33N5O4. C2H6O3S
|
|---|
| Exact mass |
649.257
|
|---|
| Mol weight |
649.7571
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
| Product (DG01374): | D10396<JP/US> |
|
|---|
| Efficacy |
Antifibrosis, Tyrosine kinase inhibitor |
|---|
| Disease |
Idiopathic pulmonary fibrosis [DS: H01299] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: UGT [KO: K00699]
Transporter: ABCB1 [HSA: 5243]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE31 Nintedanib
D10396 Nintedanib esylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Pulmonary Fibrosis Agents
Nintedanib
D10396 Nintedanib esylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D10396 Nintedanib esylate (USAN); Nintedanib ethanesulfonate (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFR
D10396 Nintedanib esylate (USAN) <JP/US>
FGFR family
FGFR1 (CD331)
D10396 Nintedanib esylate (USAN) <JP/US>
FGFR2 (CD332)
D10396 Nintedanib esylate (USAN) <JP/US>
FGFR3 (CD333)
D10396 Nintedanib esylate (USAN) <JP/US>
VEGFR family
VEGFR1 (FLT1)
D10396 Nintedanib esylate (USAN) <JP/US>
VEGFR2 (KDR)
D10396 Nintedanib esylate (USAN) <JP/US>
VEGFR3 (FLT4)
D10396 Nintedanib esylate (USAN) <JP/US>
Antineoplastics [br08340.html]
D10396
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10396
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10396
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10396
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10396
 |
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 46
1 S4a S 30.0803 -11.0132
2 O1d O 30.0803 -9.6159
3 O1d O 30.0803 -12.4804
4 C1b C 28.6830 -11.0132
5 O1d O 31.4776 -11.0132
6 C1a C 27.9843 -9.8031
7 C5a C 19.1800 -10.4300
8 N1c N 17.9900 -9.7300
9 C8y C 16.8000 -10.4300
10 C8x C 15.5400 -9.7300
11 C8y C 14.3500 -10.4300
12 C8x C 14.3500 -11.8300
13 C8x C 15.5400 -12.5300
14 C8x C 16.8000 -11.8300
15 N1b N 13.1600 -9.8000
16 O5a O 19.1800 -11.8300
17 N1y N 21.4200 -10.2200
18 C1x C 21.4200 -11.6200
19 C1x C 22.6100 -12.3200
20 N1y N 23.8000 -11.6200
21 C1x C 23.8000 -10.2200
22 C1x C 22.6100 -9.5200
23 C1a C 25.0600 -12.3200
24 C1b C 20.1600 -9.5900
25 C1a C 17.9900 -8.4000
26 C2c C 12.0400 -10.5700
27 C2y C 10.7800 -9.9400
28 C8y C 12.0400 -11.9700
29 C8x C 10.8500 -12.6700
30 C8x C 10.8500 -14.0700
31 C8x C 12.0400 -14.7700
32 C8x C 13.3000 -14.0700
33 C8x C 13.3000 -12.6700
34 C5x C 10.5700 -8.5400
35 N1x N 9.1700 -8.2600
36 C8y C 8.4700 -9.5200
37 C8y C 9.4500 -10.5700
38 O5x O 11.5500 -7.5600
39 C8x C 7.1400 -9.8700
40 C8y C 6.7200 -11.2000
41 C8x C 7.7000 -12.2500
42 C8x C 9.1000 -11.9000
43 O7a O 4.3400 -11.2000
44 C7a C 5.5300 -11.9000
45 O6a O 5.5300 -13.3000
46 C1a C 3.1500 -11.9000
BOND 49
1 1 2 2
2 1 3 2
3 1 4 1
4 1 5 1
5 4 6 1
6 9 10 2
7 10 11 1
8 11 12 2
9 12 13 1
10 13 14 2
11 14 9 1
12 11 15 1
13 7 16 2
14 7 8 1
15 8 9 1
16 17 18 1
17 18 19 1
18 19 20 1
19 20 21 1
20 21 22 1
21 22 17 1
22 20 23 1
23 17 24 1
24 7 24 1
25 8 25 1
26 15 26 1
27 26 27 2
28 26 28 1
29 28 29 2
30 29 30 1
31 30 31 2
32 31 32 1
33 32 33 2
34 28 33 1
35 27 34 1
36 34 35 1
37 35 36 1
38 36 37 1
39 27 37 1
40 34 38 2
41 36 39 2
42 39 40 1
43 40 41 2
44 41 42 1
45 37 42 2
46 43 44 1
47 44 40 1
48 44 45 2
49 43 46 1
|
|---|
